CoImmune Archives | Be Korea-savvy
CoImmune, Inc. Announces Research Collaboration with Yeda Research and Development Company Ltd.

CoImmune, Inc. Announces Research Collaboration with Yeda Research and Development Company Ltd.

DURHAM, N.C., Nov. 17 (Korea Bizwire) — CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, announced a research collaboration with Yeda Research and Development Company Ltd. (Yeda), the commercial arm of the Weizmann Institute of Science, to evaluate the applications of the Synthetic Immune Niche (SIN) technology, [...]

CoImmune, Inc. Appoints Ed Baracchini, PhD, Chairman of the Board of Directors

CoImmune, Inc. Appoints Ed Baracchini, PhD, Chairman of the Board of Directors

DURHAM, N.C., Nov. 15 (Korea Bizwire) — CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced the appointment of Dr. Ed Baracchini as chairman of the Company’s board of directors. “As a member of the CoImmune board of directors, Dr. Baracchini has provided strong counsel and [...]

CoImmune Announces Collaboration with Top U.S. Cancer Center to Accelerate Development of CAR-CIK Therapies to Treat Solid Tumors

CoImmune Announces Collaboration with Top U.S. Cancer Center to Accelerate Development of CAR-CIK Therapies to Treat Solid Tumors

DURHAM, N.C., Oct. 18 (Korea Bizwire) — CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced a license and collaboration agreement with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the adaptation of CoImmune’s proprietary allogeneic CAR-CIK technology platform to treat solid tumors. Under the terms [...]

CoImmune, Inc. to Participate in Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

CoImmune, Inc. to Participate in Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

DURHAM, N.C., Sept. 20 (Korea Bizwire) — CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced that Charles Nicolette, chief executive officer of CoImmune, will present a corporate update on September 23, 2021 at 9:05AM EDT during the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech [...]

CoImmune, Inc. Appoints Michael Fekete and Greg Tibbitts to its Board of Directors

CoImmune, Inc. Appoints Michael Fekete and Greg Tibbitts to its Board of Directors

DURHAM, N.C., July 6 (Korea Bizwire) — CoImmune, Inc., a clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class yet more affordable cellular immunotherapies, today announced the appointments of Michael Fekete and Greg Tibbitts, to the Company’s board of directors. Mr. Fekete and Mr. Tibbitts bring with them a wealth of financial, capital [...]

CoImmune, Inc. Announces Appointment of Ed Baracchini to Board of Directors

CoImmune, Inc. Announces Appointment of Ed Baracchini to Board of Directors

DURHAM, N.C., Feb. 24 (Korea Bizwire) — CoImmune, Inc., a clinical stage immuno-oncology company developing cell-based therapeutics to treat unmet medical needs in blood-borne and solid tumor indications, today announced the appointment of Dr. Edgardo Baracchini, to the Company’s board of directors. Dr. Baracchini brings a wealth of biotechnology industry and financial expertise, as well [...]

Chimeric Antigen Receptor (CAR)-modified Cytokine Induced Killer Cell (CAR-CIK) Technology Featured at ASH

Chimeric Antigen Receptor (CAR)-modified Cytokine Induced Killer Cell (CAR-CIK) Technology Featured at ASH

DURHAM, N.C., Dec. 16 (Korea Bizwire) — CoImmune, Inc. today announced that its CAR-CIK technology was featured at the annual American Society of Hematology (ASH) meeting with an interim update on the phase 1/2 dose escalation clinical trial in B-cell acute lymphoblastic leukemia (B-ALL). The trial is being conducted at Ospedale San Gerardo, Monza, Italy [...]

CoImmune, Inc. Announces Closing of $45 Million Series A Financing

CoImmune, Inc. Announces Closing of $45 Million Series A Financing

DURHAM, N.C., Nov. 10 (Korea Bizwire) — CoImmune, Inc., an immuno-oncology company developing cell-based therapeutics to treat unmet medical needs in blood-borne and solid tumor indications, today announced the closing of a $45M Series A financing. CoImmune will use the proceeds from the financing to fund its ongoing Phase 2b trial for lead asset, CMN-001, [...]

CoImmune, Inc., a US-Based Clinical-Stage Biotech, Completes Merger with Formula Pharmaceuticals, Inc.

CoImmune, Inc., a US-Based Clinical-Stage Biotech, Completes Merger with Formula Pharmaceuticals, Inc.

DURHAM, N.C. , April 30 (Korea Bizwire) — CoImmune, Inc. today announced that it has successfully completed the merger with Formula Pharmaceuticals, Inc., bringing together two therapeutic immuno-oncology platforms. Formula Pharmaceuticals merged into CoImmune with CoImmune as the surviving company. CoImmune will continue to focus on running a Phase 2b trial for lead asset, CMN-001, [...]

CoImmune, Inc. Announces FDA Approval of its IND Application to Conduct a Phase 2b Clinical Trial with CMN-001 in Advanced RCC Patients

CoImmune, Inc. Announces FDA Approval of its IND Application to Conduct a Phase 2b Clinical Trial with CMN-001 in Advanced RCC Patients

DURHAM, N.C., Feb. 19 (Korea Bizwire) — CoImmune, Inc. announced today that the FDA approved its investigational new drug application (IND) and that it is cleared to move forward with a Phase 2b clinical trial in advanced metastatic renal cell carcinoma (mRCC). CMN-001, formerly known as AGS-003, is a dendritic cell-based immunotherapy custom matched to [...]